Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Balancing toxicity and long-term QoL in HPV-positive oropharyngeal cancer

Hani Channir, MD, PhD, Rigshospitalet, Copenhagen, Denmark, comments on the importance of balancing treatment options for patients with HPV-positive oropharyngeal cancer, considering both treatment-related risks and toxicity, as well as long-term quality of life (QoL) and swallowing function. Dr Channir emphasizes the need to present these opportunities in a multidisciplinary manner, highlighting the prognosis and quality of life beyond the initial 12-month timeline. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.